Evolution of costfree resistance under fluctuating drug selection in Pseudomonas aeruginosa

mSphere

Volumn 2, Issue 4, 2017, Pages

  Melnyk, Anita H ^a   McCloskey, Nicholas ^a   Hinz, Aaron J ^a   Dettman, Jeremy ^b   Kassen, Rees ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA RESEARCH AND DEVELOPMENT CENTRE   (Canada)

Author keywords

Antibiotic resistance; Experimental evolution; Fluctuating selection; Pseudomonas aeruginosa

Indexed keywords

EID: 85041506881     PISSN: None     EISSN: 23795042     Source Type: Journal    
DOI: 10.1128/mSphere.00158-17     Document Type: Article

References (63)

1. Arason VA, Gunnlaugsson A, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG. 2002. Clonal spread of resistant pneumococci despite diminished antimicrobial use. Microb Drug Resist 8:187-192. https://doi.org/10.1089/107662902760326896
2. Sundqvist M, Geli P, Andersson DI, Sjölund-Karlsson M, Runehagen A, Cars H, Abelson-Storby K, Cars O, Kahlmeter G. 2010. Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J Antimicrob Chemother 65:350-360. https://doi.org/10 .1093/jac/dkp387
3. Enne VI, Livermore DM, Stephens P, Hall LM. 2001. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357:1325-1328. https://doi.org/10.1016/ S0140-6736(00)04519-0
4. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8:260-271. https://doi .org/10.1038/nrmicro2319
5. Enne VI. 2010. Reducing antimicrobial resistance in the community by restricting prescribing: can it be done? J Antimicrob Chemother 65: 179-182. https://doi.org/10.1093/jac/dkp443
6. Andersson DI. 2003. Persistence of antibiotic resistant bacteria. Curr Opin Microbiol 6:452-456. https://doi.org/10.1016/j.mib.2003.09.001
7. Melnyk AH, Wong A, Kassen R. 2015. The fitness costs of antibiotic resistance mutations. Evol Appl 8:273-283. https://doi.org/10.1111/eva .12196
8. Stickland HG, Davenport PW, Lilley KS, Griffin JL, Welch M. 2010. Mutation of nfxB causes global changes in the physiology and metabolism of Pseudomonas aeruginosa. J Proteome Res 9:2957-2967. https://doi.org/ 10.1021/pr9011415
9. Holberger LE, Hayes CS. 2009. Ribosomal protein S12 and aminoglycoside antibiotics modulate A-site mRNA cleavage and transfer-messenger RNA activity in Escherichia coli. J Biol Chem 284:32188-32200. https:// doi.org/10.1074/jbc.M109.062745
10. Springer B, Kidan YG, Prammananan T, Ellrott K, Böttger EC, Sander P. 2001. Mechanisms of streptomycin resistance: selection of mutations in the 16S rRNA gene conferring resistance. Antimicrob Agents Chemother 45:2877-2884. https://doi.org/10.1128/AAC.45.10.2877-2884.2001
11. Buckling A, Brockhurst MA, Travisano M, Rainey PB. 2007. Experimental adaptation to high and low quality environments under different scales of temporal variation. J Evol Biol 20:296-300. https://doi.org/10.1111/j .1420-9101.2006.01195.x
12. Kassen R. 2002. The experimental evolution of specialists, generalists, and the maintenance of diversity. J Evol Biol 15:173-190. https://doi.org/ 10.1046/j.1420-9101.2002.00377.x
13. Turner PE, Elena SF. 2000. Cost of host radiation in an RNA virus. Genetics 156:1465-1470
14. Kassen R, Bell G. 1998. Experimental evolution in Chlamydomonas. IV. Selection in environments that vary through time at different scales. Heredity 80:732-741. https://doi.org/10.1046/j.1365-2540.1998.00329.x
15. Borrell S, Teo Y, Giardina F, Streicher EM, Klopper M, Feldmann J, Müller B, Victor TC, Gagneux S. 2013. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evol Med Publ Health 2013:65-74. https://doi.org/10.1093/emph/eot003
16. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, Gagneux S. 2012. Whole-genome sequencing of rifampicinresistant M. tuberculosis strains identifies compensatory mutations in RNA polymerase. Nat Genet 44:106-110
17. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJM. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944-1946. https://doi.org/10.1126/science .1124410
18. Björkholm B, Sjölund M, Falk PG, Berg OG, Engstrand L, Andersson DI. 2001. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc Natl Acad Sci U S A 98:14607-14612. https://doi .org/10.1073/pnas.241517298
19. Nagaev I, Björkman J, Andersson DI, Hughes D. 2001. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 40:433-439. https://doi.org/10.1046/j.1365-2958.2001 .02389.x
20. Levin BR, Perrot V, Walker N. 2000. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154:985-997
21. Björkman J, Nagaev I, Berg OG, Hughes D, Andersson DI. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287:1479-1482
22. Kassen R, Bataillon T. 2006. Distribution of fitness effects among beneficial mutations before selection in experimental populations of bacteria. Nat Genet 38:484-488. https://doi.org/10.1038/ng1751
23. Ramadhan AA, Hegedus E. 2005. Survivability of vancomycin resistant enterococci and fitness cost of vancomycin resistance acquisition. J Clin Pathol 58:744-746. https://doi.org/10.1136/jcp.2004.024091
24. Gillespie SH, Voelker LL, Dickens A. 2002. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb Drug Resist 8:79-84. https://doi.org/10.1089/107662902760190617
25. Pym AS, Saint-Joanis B, Cole ST. 2002. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 70:4955-4960. https://doi.org/10 .1128/IAI.70.9.4955-4960.2002
26. Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, Pletschette M, Böttger EC. 2002. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 46: 1204-1211. https://doi.org/10.1128/AAC.46.5.1204-1211.2002
27. Böttger EC, Springer B, Pletschette M, Sander P. 1998. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 4:1343-1344. https://doi.org/10.1038/3906
28. Canadian Cystic Fibrosis Foundation. 2011. Canadian Cystic Fibrosis Foundation: Annual Report. Canadian Cystic Fibrosis Foundation, Toronto, Ontario, Canada
29. U.K. Cystic Fibrosis Trust Antibiotic Working Group. 2009. Antibiotic treatment for cystic fibrosis, 3rd ed. Cystic Fibrosis Trust, London, United Kingdom
30. Hancock REW, Speert DP. 2000. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat 3:247-255. https://doi.org/10.1054/drup.2000.0152
31. Wu YL, Scott EM, Po AL, Tariq VN. 1999. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations. APMIS 107:585-592. https://doi.org/10.1111/j .1699-0463.1999.tb01596.x
32. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. 2010. Antibiotic resistance of bacterial biofilms. Int J Antimicro Agents 35:322-332. https://doi.org/10.1016/j.ijantimicag.2009.12.011
33. Sordé R, Pahissa A, Rello J. 2011. Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis. Infect Drug Resist 4:31-41. https://doi.org/10.2147/IDR.S16263
34. Bhatt JM. 2013. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 22:205-216. https://doi.org/10.1183/09059180.00006512
35. Silva Filho LV, Ferreira Fde A, Reis FJ, Britto MC, Levy CE, Clark O, Ribeiro JD. 2013. Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. J Bras Pneumol 39:495-512. https://doi.org/10.1590/S1806-37132013000400015
36. Fricks-Lima J, Hendrickson CM, Allgaier M, Zhuo H, Wiener-Kronish JP, Lynch SV, Yang K. 2011. Differences in biofilm formation and antimicrobial resistance in Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients. Int J Antimicro Agric 37: 309-315. https://doi.org/10.1016/j.ijantimicag.2010.12.017
37. Pedersen SS, Jensen T, Hvidberg EF. 1987. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. J Antimicrob Chemother 20:575-583. https://doi.org/10.1093/jac/20.4.575
38. Wong A, Rodrigue N, Kassen R. 2012. Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosa. PLoS Genet 8:e1002928. https://doi.org/10.1371/journal .pgen.1002928
39. Schoustra SE, Bataillon T, Gifford DR, Kassen R. 2009. The properties of adaptive walks in evolving populations of fungus. PLoS Biol 7:e1000250. https://doi.org/10.1371/journal.pbio.1000250
40. Jørgensen KM, Wassermann T, Jensen PØ, Hengzuang W, Molin S, Høiby N, Ciofu O. 2013. Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:4215-4221. https://doi.org/10.1128/AAC.00493-13
41. Marvig RL, Sommer LM, Molin S, Johansen HK. 2015. Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat Genet 47:57-64. https://doi.org/10.1038/ng.3148
42. Marvig RL, Johansen HK, Molin S, Jelsbak L. 2013. Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. PLoS Genet 9:e1003741. https://doi.org/10.1371/journal.pgen.1003741
43. Oliver A, Levin BR, Juan C, Baquero F, Blázquez J. 2004. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother 48:4226-4233. https://doi .org/10.1128/AAC.48.11.4226-4233.2004
44. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254. https://doi.org/10.1126/science.288 .5469.1251
45. Jacoby GA. 2005. Mechanisms of resistance to quinolones. Clin Infect Dis 41:S120-S126. https://doi.org/10.1086/428052
46. Ruiz J. 2003. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51:1109-1117. https://doi.org/10.1093/jac/dkg222
47. Poole K. 2005. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56:20-51. https://doi.org/10.1093/jac/dki171
48. Barnard FM, Maxwell A. 2001. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit resides Ser83 and Asp87. Antimicrob Agents Chemother 45:1994-2000. https://doi .org/10.1128/AAC.45.7.1994-2000.2001
49. Yoshida H, Bogaki M, Nakamura M, Nakamura S. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 34:1271-1272. https://doi.org/ 10.1128/AAC.34.6.1271
50. Yoshida H, Nakamura M, Bogaki M, Nakamura S. 1990. Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 34:1273-1275. https://doi .org/10.1128/AAC.34.6.1273
51. Bruchmann S, Dötsch A, Nouri B, Chaberny IF, Häussler S. 2013. Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrob Agents Chemother 57:1361-1368. https://doi.org/10.1128/AAC .01581-12
52. Wolfe AJ, Visick KL. 2008. Get the message out: cyclic-di-GMP regulates multiple levels of flagellum-based motility. J Bacteriol 190:463-475. https://doi.org/10.1128/JB.01418-07
53. Meissner A, Wild V, Simm R, Rohde M, Erck C, Bredenbruch F, Morr M, Römling U, Häussler S. 2007. Pseudomonas aeruginosa cupA-encoded fimbriae expression is regulated by a GGDEF and EAL domain-dependent modulation of the intracellular level of cyclic diguanylate. Environ Microbiol 9:2475-2485. https://doi.org/10.1111/j.1462-2920.2007.01366.x
54. Hickman JW, Tifrea DF, Harwood CS. 2005. A chemosensory system that regulates biofilm formation through modulation of cyclic diguanylate levels. Proc Natl Acad Sci U S A 102:14422-14427. https://doi.org/10 .1073/pnas.0507170102
55. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV. 2006. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103: 8487-8492. https://doi.org/10.1073/pnas.0602138103
56. Bailey SF, Rodrigue N, Kassen R. 2015. The effect of selection environment on the probability of parallel evolution. Mol Biol Evol 32: 1436-1448. https://doi.org/10.1093/molbev/msv033
57. Rainey PB. 1999. Adaptation of Pseudomonas fluorescens to the plant rhizosphere. Environ Microbiol 1:243-257. https://doi.org/10.1046/j.1462-2920.1999.00040.x
58. Wong A, Kassen R. 2011. Parallel evolution and local differentiation in quinolone resistance in Pseudomonas aeruginosa. Microbiology 157: 937-944. https://doi.org/10.1099/mic.0.046870-0
59. Kim S, Lieberman TD, Kishony R. 2014. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc Natl Acad Sci U S A 111:14494-14499. https://doi.org/10.1073/pnas.1409800111
60. Houle D, Pélabon C, Wagner GP, Hansen TF. 2011. Measurement and meaning in biology. Q Rev Biol 86:3-34. https://doi.org/10.1086/ 658408
61. R Core Team. 2013. R:A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http:// www.R-project.org/
62. Dettman JR, Rodrigue N, Melnyk AH, Wong A, Bailey SF, Kassen R. 2012. Evolutionary insight from whole-genome sequencing of experimentally evolved microbes. Mol Ecol 21:2058-2077. https://doi.org/10.1111/j .1365-294X.2012.05484.x
63. Winsor GL, Lam DK, Fleming L, Lo R, Whiteside MD, Yu NY, Hancock RE, Brinkman FS. 2011. Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes. Nucleic Acids Res 39:D596-D600. https://doi.org/10.1093/nar/ gkq869